0.00399429386590586 0 0.00213980028530658 0.00356633380884451 0.00356633380884451 0.00499286733238223 0.00684736091298131 0.00713266761768902
Sign Up Today X
Thanks for submitting the form.
Stockreport

U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool]

Gilead Sciences, Inc. (GILD)  More Company Research Source: The Motley Fool
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
On Tuesday, officials from the National Institute of Health (NIH) announced the initiation of a clinical trial in which patients in U.S. hospitals with confirmed COVID-9 infections will be given Gilead Sciences' NASDAQ:GILD What we know The first clinical trial participant was an American currently at the Nebraska Medical Center in Omaha, who had been quarantined with other infected passengers from the Diamond Princess cruise ship. Image source: Getty Images. While we can be fairly certain the first trial participant won't be in a hurry to take another cruise, that's really all we know about this person at the moment. The NIH and Gilead Sciences will most likely randomize patients into groups receiving remdesivir or a placebo, so don't discount remdesivir's potential as a COVID-9 treatment if you don't see news of about the rapid recovery from that first enrolled U.S. patient in the next couple of days. Health officials at the China-Japan Friendship Hospital and other centers in Hubei [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

U.S. Health Officials Start First Clinical Trial With Gilead Sciences' Experimental Coronavirus Treatment [The Motley Fool]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: The Motley Fool
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
On Tuesday, officials from the National Institute of Health (NIH) announced the initiation of a clinical trial in which patients in U.S. hospitals with confirmed COVID-9 infections will be given Gilead Sciences' NASDAQ:GILD What we know The first clinical trial participant was an American currently at the Nebraska Medical Center in Omaha, who had been quarantined with other infected passengers from the Diamond Princess cruise ship. Image source: Getty Images. While we can be fairly certain the first trial participant won't be in a hurry to take another cruise, that's really all we know about this person at the moment. The NIH and Gilead Sciences will most likely randomize patients into groups receiving remdesivir or a placebo, so don't discount remdesivir's potential as a COVID-9 treatment if you don't see news of about the rapid recovery from that first enrolled U.S. patient in the next couple of days. Health officials at the China-Japan Friendship Hospital and other centers in Hubei [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS